600153-19-3

Basic information

• Product Name: (S)-3-(2-Aminooxy-acetylamino)-2-(6-{3-[(2S,5S,11S,14R)-14-benzyl-11-carboxymethyl-5-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-propionylamino}-hexanoylamino)-propionic acid
• Synonyms: (S)-3-(2-Aminooxy-acetylamino)-2-(6-{3-[(2S,5S,11S,14R)-14-benzyl-11-carboxymethyl-5-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-propionylamino}-hexanoylamino)-propionic acid
• CAS NO: 600153-19-3
• Molecular Weight: 876.924
• Mol File: 600153-19-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-3-(2-Aminooxy-acetylamino)-2-(6-{3-[(2S,5S,11S,14R)-14-benzyl-11-carboxymethyl-5-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-propionylamino}-hexanoylamino)-propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-(2-Aminooxy-acetylamino)-2-(6-{3-[(2S,5S,11S,14R)-14-benzyl-11-carboxymethyl-5-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-propionylamino}-hexanoylamino)-propionic acid(600153-19-3)
• EPA Substance Registry System: (S)-3-(2-Aminooxy-acetylamino)-2-(6-{3-[(2S,5S,11S,14R)-14-benzyl-11-carboxymethyl-5-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-propionylamino}-hexanoylamino)-propionic acid(600153-19-3)

Safety Data

• Hazardous Substances Data: 600153-19-3(Hazardous Substances Data)

Upstream product

• 86123-10-6 Fmoc-D-Phe-OH 
• 123639-61-2 Fmoc-L-glutamic acid-g-benzyl ester 
• 88574-06-5 6-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoic acid 
• 600153-12-6 N-α-Fmoc-N-β-(N-tert-butyloxycarbonylaminooxyacetal)-L-diaminopropionic acid 

Relevant articles and documents

Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation

The αvβ3 integrin receptor plays an important role in human metastasis and tumor-induced angiogenesis. Targeting this receptor may provide information about the receptor status of the tumor and enable specific therapeutic planning. Solid-phase peptide synthesis of multimeric cyclo(-RGDfE-)-peptides is described, which offer the possibility of enhanced integrin targeting due to polyvalency effects. These peptides contain an aminooxy group for versatile chemoselective oxime ligation. Conjugation with para-trimethylstannylbenzaldehyde results in a precursor for radioiododestannylation, which would allow them to be used as potential tools for targeting and imaging αvβ3-expressing tumor cells. The conjugates were obtained in good yield without the need of a protection strategy and under mild conditions.